Cytopia selects drug candidate for myeloproliferative disorders

This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. CYT387 is claimed to possess an excellent selectivity profile against a large panel of kinases and other pharmacological targets. It also has excellent pharmacokinetics including oral bioavailability and in preclinical models has a promising safety profile.

Andrew Macdonald, CEO of Cytopia, said: “We are aggressively advancing this compound through formal preclinical studies with the aim of beginning clinical trials by the end of 2008.”